...
机译:先进阶段非小细胞肺癌患者的响应和存活深度之间的关联
Washington University School of MedicineSt. Louis Missouri;
Celgene CorporationSummit New Jersey;
Royal Marsden NHS Foundation TrustLondon United Kingdom;
Celgene CorporationSummit New Jersey;
Washington University School of MedicineSt. Louis Missouri;
Florida Hospital Cancer InstituteOrlando Florida;
Leiden UniversityLeiden the Netherlands;
Celgene CorporationSummit New Jersey;
depth of response; first‐line chemotherapy; non–small cell lung cancer (NSCLC); overall survival; Response Evaluation Criteria in Solid Tumors (RECIST);
机译:先进阶段非小细胞肺癌患者的响应和存活深度之间的关联
机译:ERCC1-C118T和-C8092A多态性与肺癌风险和肺癌患者患者的肺癌危险和存活率接受铂类化疗:基于39报告的汇总分析
机译:ERCC1表达未预测铂化疗治疗的先进阶段非小细胞肺癌病例中的存活和治疗反应
机译:培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
机译:评估姑息化疗对非小细胞肺癌的有效性:在安大略省癌症中心接受治疗的患者的IV期研究
机译:EGFR-TKI治疗晚期非小细胞肺癌患者反应深度与无进展生存期相关
机译:先进阶段非小细胞肺癌患者响应和存活深度的关系